Elevance Health (NYSE:ELV) Announces Earnings Results, Beats Estimates By $0.04 EPS

Elevance Health (NYSE:ELV) released its earnings results on Thursday. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.80 by $0.04, Zacks reports. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. Elevance Health updated its FY 2025 guidance to 34.150-34.850 EPS.

Elevance Health Price Performance

ELV stock traded up $3.19 on Thursday, reaching $393.92. The company had a trading volume of 539,696 shares, compared to its average volume of 1,712,752. The company’s fifty day moving average is $386.32 and its 200 day moving average is $463.64. The company has a market cap of $91.36 billion, a P/E ratio of 14.44, a PEG ratio of 1.10 and a beta of 0.84. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50. Elevance Health has a 1 year low of $362.21 and a 1 year high of $567.26.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be paid a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.74%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s dividend payout ratio (DPR) is 23.77%.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELV. Wells Fargo & Company lowered their price objective on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. StockNews.com raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Friday, January 17th. UBS Group decreased their price target on Elevance Health from $605.00 to $555.00 and set a “buy” rating for the company in a report on Friday, October 18th. Truist Financial dropped their price objective on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Argus downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $524.87.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.